SynthesisObesity surgery2025
The Role of Tranexamic Acid (TXA) on Postoperative Bleeding in Bariatric Surgery: A Systematic Review and Meta-Analysis.
Synthesis in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and Safety of Tranexamic Acid Use in Bariatric Surgery: An Updated Systematic Review and Meta-Analysis.Obesity surgery · 2026Pooled it
- Efficacy and safety of tranexamic acid during bariatric surgery: an updated systematic review and meta-analysis of 10 comparative studies.BMC surgery · 2025Pooled it
- Efficacy and Safety of Tranexamic Acid in Sleeve Gastrectomy: A Double-Blind Randomized Controlled Trial.Obesity surgery · 2026Trial
- Prophylactic Tranexamic Acid as Prevention for Early Postoperative Bleeding after Roux-en-Y Gastric Bypass.Obesity surgery · 2026Article
- Perioperative Tranexamic Acid Reduces Bleeding and Wound Complications in Post-Bariatric Abdominoplasty: A Retrospective Cohort Study.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent research highlights TXA's potential in managing postoperative bleeding in bariatric surgery, prompting us to evaluate its effectiveness for treatment and prophylaxis. PubMed, Scopus, Cochrane Central, SciElo, and LILACS were searched for TXA studies in bariatric surgery, excluding those without control groups or with overlapping populations. Outcome analysis focused on postoperative bleeding, length of hospital stay (LOS), TXA side effects, mortality, transfusion needs, and thromboembolic complications. From 93 results, six studies involving 1121 patients were included. TXA use significantly decreased the LOS (MD = - 0.12; 95% CI, - 0.18, - 0.06; p < 0.01), operative time (MD = - 5.77; 95% CI, - 9.98, - 1.56; p < 0.01), and postoperative bleeding (OR = 0.57; 95% CI, 0.34, 0.98; p = 0.043). However, TXA did not affect the rate of hematoma formation (OR = 0.39; 95% CI, 0.07, 2.29; p = 0.299), rate of reoperation (OR = 0.46; 95% CI, 0.08, 2.82; p = 0.403), or need for transfusion (OR = 0.25; 95% CI, 0.06, 1.07; p = 0.062). There were no thromboembolic events or mortality. TXA significantly reduces LOS, operative time, and postoperative bleeding in bariatric surgery without affecting reoperation rates. This medication appears to be safe in this population as it did not increase the risk of thromboembolic events.
Indexed as
Identifiers
40072741What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.